These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 19842076)
1. [Clinical experience with pegaptanib in the treatment of age-related macular degeneration (AMD)]. Thelen U Klin Monbl Augenheilkd; 2010 Jan; 227(1):67-72. PubMed ID: 19842076 [TBL] [Abstract][Full Text] [Related]
2. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib]. Maier M; Feucht N; Huebner M; Lohmann C Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780 [TBL] [Abstract][Full Text] [Related]
3. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. ; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134 [TBL] [Abstract][Full Text] [Related]
4. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib. Quiram PA; Hassan TS; Williams GA Retina; 2007 Sep; 27(7):851-6. PubMed ID: 17891008 [TBL] [Abstract][Full Text] [Related]
5. Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration. Williams AJ; Fekrat S Am J Ophthalmol; 2006 Oct; 142(4):683-4. PubMed ID: 17011868 [TBL] [Abstract][Full Text] [Related]
7. RPE tears after pegaptanib treatment in age-related macular degeneration. Chang LK; Flaxel CJ; Lauer AK; Sarraf D Retina; 2007 Sep; 27(7):857-63. PubMed ID: 17891009 [TBL] [Abstract][Full Text] [Related]
8. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration. Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685 [TBL] [Abstract][Full Text] [Related]
9. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. ; Chakravarthy U; Adamis AP; Cunningham ET; Goldbaum M; Guyer DR; Katz B; Patel M Ophthalmology; 2006 Sep; 113(9):1508.e1-25. PubMed ID: 16828500 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Hughes MS; Sang DN Ophthalmic Surg Lasers Imaging; 2006; 37(6):446-54. PubMed ID: 17152537 [TBL] [Abstract][Full Text] [Related]
11. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. ; Apte RS; Modi M; Masonson H; Patel M; Whitfield L; Adamis AP Ophthalmology; 2007 Sep; 114(9):1702-12. PubMed ID: 17509689 [TBL] [Abstract][Full Text] [Related]